New Zealand markets open in 2 hours 27 minutes

VBI Vaccines Inc. (LO9A.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.5400-0.0200 (-3.57%)
At close: 08:20AM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 15.85M
Enterprise value 51.46M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.20
Price/book (mrq)0.66
Enterprise value/revenue 5.85
Enterprise value/EBITDA -0.64

Trading information

Stock price history

Beta (5Y monthly) 1.99
52-week change 3-72.59%
S&P500 52-week change 326.24%
52-week high 32.9200
52-week low 30.4200
50-day moving average 30.5589
200-day moving average 30.5724

Share statistics

Avg vol (3-month) 3215
Avg vol (10-day) 3N/A
Shares outstanding 528.68M
Implied shares outstanding 629.36M
Float 826.73M
% held by insiders 16.77%
% held by institutions 113.03%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 312 Apr 2023

Financial highlights

Currency in USD.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-968.04%

Management effectiveness

Return on assets (ttm)-29.15%
Return on equity (ttm)-419.59%

Income statement

Revenue (ttm)9.41M
Revenue per share (ttm)0.48
Quarterly revenue growth (yoy)150.30%
Gross profit (ttm)N/A
EBITDA -45.58M
Net income avi to common (ttm)-83.99M
Diluted EPS (ttm)-3.3100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.6M
Total cash per share (mrq)0.44
Total debt (mrq)50.71M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.34
Book value per share (mrq)-0.22

Cash flow statement

Operating cash flow (ttm)-51M
Levered free cash flow (ttm)-29.1M